Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712498 | 1.00 | MAPT (0.40) | MAPTALDH1A1TSHRHTTATM | |
| SCHEMBL8665536 | 0.80 | ALDH1A1 (0.46) | MAPTALDH1A1TSHRHTTATM | |
| SCHEMBL9845929 | 0.75 | ATM (0.39) | MAPTALDH1A1TSHRHTTATM | |
| SCHEMBL18650110 | 0.73 | ALDH1A1 (0.39) | MAPTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL10193490 | 0.69 | ALDH1A1 (0.32) | MAPTALDH1A1CYP2C9MEN1KMT2A | |
| SCHEMBL17916180 | 0.68 | ALDH1A1 (0.36) | MAPTALDH1A1CYP2C9MEN1KMT2A | |
| SCHEMBL7775723 | 0.68 | ALDH1A1 (0.41) | MAPTALDH1A1TSHRHTTATM | |
| SCHEMBL3803101 | 0.67 | ALDH1A1 (0.38) | MAPTALDH1A1TSHRCYP2C9CYP2C19 | |
| SCHEMBL10122037 | 0.67 | ALDH1A1 (0.38) | MAPTALDH1A1TSHRCYP2C9CYP2C19 | |
| SCHEMBL3803095 | 0.67 | ALDH1A1 (0.38) | MAPTALDH1A1TSHRCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735352-B1 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | CALIFORNIA INST OF TECHN (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9238709-B2 | Latent, high-activity olefin metathesis catalysts containing an N-heterocyclic carbene ligand | MATERIA, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150141603-A1 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | disclosed |
| US-8871879-B2 | Latent, high-activity olefin metathesis catalysts containing an N-heterocyclic carbene ligand | MATERIA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130296511-A1 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-07 | — | — | US | disclosed |
| EP-1735352-A2 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050261451-A1 | Latent, high-activity olefin metathesis catalysts containing an N-heterocyclic carbene ligand | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005094345-A2 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261451-A1 | Latent, high-activity olefin metathesis catalysts containing an N-heterocyclic carbene ligand | CDK8, LTC4S, ZCCHC8 | MAPT 3653/4885ALDH1A1 1944/4885TSHR 4609/4885 |
| US-20130296511-A1 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | CDK8, LTC4S, ZCCHC8 | MAPT 3653/4885ALDH1A1 1944/4885TSHR 4609/4885 |
| US-20150141603-A1 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | CDK8, LTC4S, ZCCHC8 | MAPT 3653/4885ALDH1A1 1944/4885TSHR 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.